Company / Operating Cash Flow
GeneDx Holdings Corp. Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$33.3M
FY2025
5-year range
-$319.2M / $33.3M
FY2021-FY2025
Trend
+216.8%
vs FY2024
Sector context
#123 of 158
Health Care
What the data says
Operating Cash Flow changed +217% YoY in FY2025, a notable deviation from the 6-year average annual change of -37%.
Based on SEC 10-K filings.
$33M in FY2025.
Improved from -$180M to $33M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 158This company $33.3M Sector average $1.0B
▼
-96.8% below sector average
Key checks
Key Insights
- GeneDx Holdings Corp.'s operating cash flow has grown for 3 consecutive years.
- In FY2025, operating cash flow increased 216.8% year-over-year.
- Ranks #123 out of 158 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $33.3M | +216.8% |
| FY2024 | -$28.5M | +84.2% |
| FY2023 | -$180.1M | +43.6% |
| FY2022 | -$319.2M | -67.6% |
| FY2021 | -$190.4M | -104.5% |
| FY2020 | -$93.1M | -397.3% |
| FY2019 | -$18.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026